Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
How machine intelligence changes the rules of business by Marco Iansiti and Karim R. Lakhani In 2019, just five years after the Ant Financial Services Group was launched, the number of consumers using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results